Review



cd16 antibody, anti-human, reafinity  (Miltenyi Biotec)


Bioz Verified Symbol Miltenyi Biotec is a verified supplier
Bioz Manufacturer Symbol Miltenyi Biotec manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 93
      Buy from Supplier

    Structured Review

    Miltenyi Biotec cd16 antibody, anti-human, reafinity
    Cd16 Antibody, Anti Human, Reafinity, supplied by Miltenyi Biotec, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/cd16/CD16+Antibody%2C+anti-human%2C+REAfinity/custom%40130-128-774%4042502392
    Average 93 stars, based on 1 article reviews
    cd16 antibody, anti-human, reafinity - by Bioz Stars, 2026-09
    93/100 stars

    Images

    Related Articles

    Isolation:

    Article Title: Single domain antibodies and their use in cancer therapies
    Article Snippet: T Cell Isolation and Transduction Peripheral blood mononuclear cells (PBMCs) were recovered using the density gradient LymphoprepTM (StemCells). .. CD8+ T cells were isolated by negative selection using a cocktail containing antibodies against CD4, CD15, CD16, CD19, CD34, CD36, CD56, CD123, TCRγ/δ, and CD235a (Glycophorin A), according to the instruction of CD8+ T cell human isolation kit (Miltenyi). .. Isolated CD8+ T cells were then cultured in X-VIVO® medium (Lonza) supplemented with 50 μM of β-mercaptoethanol (Merck Millipore) and 5% Human Serum (Merck Millipore) and activated using Human T-activator CD3/CD28 Dynabeads® (Gibco) following the manufacture instructions.

    Selection:

    Article Title: Single domain antibodies and their use in cancer therapies
    Article Snippet: T Cell Isolation and Transduction Peripheral blood mononuclear cells (PBMCs) were recovered using the density gradient LymphoprepTM (StemCells). .. CD8+ T cells were isolated by negative selection using a cocktail containing antibodies against CD4, CD15, CD16, CD19, CD34, CD36, CD56, CD123, TCRγ/δ, and CD235a (Glycophorin A), according to the instruction of CD8+ T cell human isolation kit (Miltenyi). .. Isolated CD8+ T cells were then cultured in X-VIVO® medium (Lonza) supplemented with 50 μM of β-mercaptoethanol (Merck Millipore) and 5% Human Serum (Merck Millipore) and activated using Human T-activator CD3/CD28 Dynabeads® (Gibco) following the manufacture instructions.

    Incubation:

    Article Title: Differential Responses of Human iPSC-Derived Microglia to Stimulation with Diverse Inflammogens.
    Article Snippet: The supernatant was removed, and the cells were re-suspended in 50 μL Viobility staining solution (diluted 1:100 in DPBS; Miltenyi Biotech, Bergisch Gladbach, Germany) and incubated for 10 min in the dark. .. After incubation, 1 μL of a pre-mix containing equal parts of the antibodies CD11b, CD14, and CD16 (Miltenyi Biotech, Bergisch Gladbach, Germany) was added to the tube for staining, followed by another 10 min incubation in the dark. ..

    Staining:

    Article Title: Differential Responses of Human iPSC-Derived Microglia to Stimulation with Diverse Inflammogens.
    Article Snippet: The supernatant was removed, and the cells were re-suspended in 50 μL Viobility staining solution (diluted 1:100 in DPBS; Miltenyi Biotech, Bergisch Gladbach, Germany) and incubated for 10 min in the dark. .. After incubation, 1 μL of a pre-mix containing equal parts of the antibodies CD11b, CD14, and CD16 (Miltenyi Biotech, Bergisch Gladbach, Germany) was added to the tube for staining, followed by another 10 min incubation in the dark. ..

    Article Title: The Neutrophil-to-Albumin Ratio (NAR) Reflects the Severity of the Post-CABG Inflammatory Response and Is Associated with a Pre-Existing Pro-Inflammatory Monocyte Profile
    Article Snippet: Plasma levels of Interleukin-6 (IL-6) were measured using a commercially available high-sensitivity enzyme-linked immunosorbent assay (ELISA) kit (R&D Systems, Minneapolis, MN, USA). .. A 50 μL aliquot of the leucocyte fraction was stained with fluorescently conjugated monoclonal antibodies against CD14 (FITC conjugate) and CD16 (PB450-A conjugate) (Miltenyi Biotec, Bergisch Gladbach, Germany). ..

    Article Title: Enhanced solid tumor cell targeting by a neoepitope-encoding oncolytic measles virus combined with CAR therapy
    Article Snippet: For detection of CAR-T and CAR-NK cell counts after the coculture, CAR-T cells were labeled with 1 μM CellTrace Violet and 1 μM CellTrace FarRed according to the manufacturer’s instructions, respectively (Thermo Fisher Scientific, Waltham, MA, USA). .. For evaluation of CAR-T and CAR-NK cell activation following coculture with tumor cells and MV, staining with CD3 (CD3 antibody, VioBlue, anti-human, REAfinity), CD16 (CD16 antibody, anti-human, PerCP-Vio700, REAfinity), OX40 (CD134 antibody, PerCP-Vio700, anti-human, REAfinity), NKG2D (CD314 antibody, PE, anti-human, REAfinity), DNAM-1 (CD226 antibody, PE-Vio770, anti-human, REAfinity), 2B4 (CD244 antibody, APC, anti-human, REAfinity), CD48 (CD48 Antibody, APC-Vio770, anti-human, REAfinity) (all Miltenyi Biotec, Bergisch Gladbach, Germany), and OX40L (CD252 antibody, BV421, anti-human) (Becton Dickinson [BD], New Jersey, USA) was carried out after 72 h of coculture. ..

    Membrane:

    Article Title: Circulating monocytes from systemic sclerosis patients with progressive interstitial lung disease preferentially express M2 phenotype markers: in vitro and ex vivo study.
    Article Snippet: .. A total of 5×106 cells and detecting more than 30 events in the smallest subset were investigated.37 38 The gating strategy used in this study started from the detection of the monocyte population characterised as CD45+CD14+CD16+cells in the leucocyte population (CD45+cells) excluding both lymphocytes and granulocytes, as it has been shown in the online supplemental file 2 and recently described in our recent study.30 The monocyte lineage was characterised by investigating the cell membrane markers CD14, CD16 and CD45, using conjugated primary antibodies anti- human CD14- FITC (Miltenyi Biotech, Bergisch Gladbach, Germany), CD16- APC AlexaFluor 700, and CD45- Krome Orange (Beckman Coulter). .. The M1 phenotype of circulating monocytes was defined through the detection of cell membrane markers CD80 and TLR4 using conjugated primary antibodies anti- human CD80- PEVio770 (Miltenyi Biotech) and TLR4- BV421 (Becton Dickinson- BD Biosciences, Franklin Lakes, New Jersey, USA), whereas to identify M2 phenotype, the specific cell membrane markers CD163, CD204 and CD206 were investigated using conjugated primary antibodies anti- human CD163- PEVio615, CD204- PE and CD206- PerCPVio700 (Miltenyi Biotech).

    other:

    Article Title: Acute COVID-19 is associated with altered CD8 T-cells indicative of impaired ability to control Epstein–Barr virus reactivation
    Article Snippet: CD16 , APC-Vio 770 , REA423 , Miltenyi Biotec , 130-113-390 , AB_2733101.

    Bioprocessing:

    Article Title: The Neutrophil-to-Albumin Ratio (NAR) Reflects the Severity of the Post-CABG Inflammatory Response and Is Associated with a Pre-Existing Pro-Inflammatory Monocyte Profile
    Article Snippet: Plasma levels of Interleukin-6 (IL-6) were measured using a commercially available high-sensitivity enzyme-linked immunosorbent assay (ELISA) kit (R&D Systems, Minneapolis, MN, USA). .. A 50 μL aliquot of the leucocyte fraction was stained with fluorescently conjugated monoclonal antibodies against CD14 (FITC conjugate) and CD16 (PB450-A conjugate) (Miltenyi Biotec, Bergisch Gladbach, Germany). ..

    Activation Assay:

    Article Title: Enhanced solid tumor cell targeting by a neoepitope-encoding oncolytic measles virus combined with CAR therapy
    Article Snippet: For detection of CAR-T and CAR-NK cell counts after the coculture, CAR-T cells were labeled with 1 μM CellTrace Violet and 1 μM CellTrace FarRed according to the manufacturer’s instructions, respectively (Thermo Fisher Scientific, Waltham, MA, USA). .. For evaluation of CAR-T and CAR-NK cell activation following coculture with tumor cells and MV, staining with CD3 (CD3 antibody, VioBlue, anti-human, REAfinity), CD16 (CD16 antibody, anti-human, PerCP-Vio700, REAfinity), OX40 (CD134 antibody, PerCP-Vio700, anti-human, REAfinity), NKG2D (CD314 antibody, PE, anti-human, REAfinity), DNAM-1 (CD226 antibody, PE-Vio770, anti-human, REAfinity), 2B4 (CD244 antibody, APC, anti-human, REAfinity), CD48 (CD48 Antibody, APC-Vio770, anti-human, REAfinity) (all Miltenyi Biotec, Bergisch Gladbach, Germany), and OX40L (CD252 antibody, BV421, anti-human) (Becton Dickinson [BD], New Jersey, USA) was carried out after 72 h of coculture. ..



    Similar Products

    jurkat-lucia nfat-cd16-low cells  (InvivoGen)
    96
    InvivoGen jurkat-lucia nfat-cd16-low cells
    Jurkat Lucia Nfat Cd16 Low Cells, supplied by InvivoGen, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/cd16/Jurkat-Lucia+NFAT-CD16-Low+Cells/custom%40jktl-nfat-cd16lo%4042675026
    Average 96 stars, based on 1 article reviews
    jurkat-lucia nfat-cd16-low cells - by Bioz Stars, 2026-09
    96/100 stars
    		  Buy from Supplier
    cd16 antibody, anti-human, reafinity  (Miltenyi Biotec)
    93
    Miltenyi Biotec cd16 antibody, anti-human, reafinity
    Cd16 Antibody, Anti Human, Reafinity, supplied by Miltenyi Biotec, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/cd16/CD16+Antibody%2C+anti-human%2C+REAfinity/custom%40130-128-774%4042502392
    Average 93 stars, based on 1 article reviews
    cd16 antibody, anti-human, reafinity - by Bioz Stars, 2026-09
    93/100 stars
    		  Buy from Supplier
    cd16 cd32  (Miltenyi Biotec)
    96
    Miltenyi Biotec cd16 cd32
    Cd16 Cd32, supplied by Miltenyi Biotec, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/cd16/Streptavidin+MicroBeads/pm42393099-238-15-16
    Average 96 stars, based on 1 article reviews
    cd16 cd32 - by Bioz Stars, 2026-09
    96/100 stars
    		  Buy from Supplier
    ultra leaftm purified anti mouse cd16 32  (Miltenyi Biotec)
    97
    Miltenyi Biotec ultra leaftm purified anti mouse cd16 32
    Ultra Leaftm Purified Anti Mouse Cd16 32, supplied by Miltenyi Biotec, used in various techniques. Bioz Stars score: 97/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/cd16/FcR+Blocking+Reagent%2C+mouse/pm42392075-361-42-56
    Average 97 stars, based on 1 article reviews
    ultra leaftm purified anti mouse cd16 32 - by Bioz Stars, 2026-09
    97/100 stars
    		  Buy from Supplier
    cd16 pe  (Miltenyi Biotec)
    95
    Miltenyi Biotec cd16 pe
    Flow immunophenotyping release testing data are presented in A-G and IFNγ ELISpot data presented in H-K (Arm A: n = 12; Arms B/C: n = 27). Each data point represents a separate TAA-T cell product infused into patients (biological replicates). Lower whisker is defined as the minima, upper whisker is defined as the maxima, center is defined as median, lower bound of box is defined as Q1 (25th percentile), and upper bound of box is defined as Q3 (75th percentile). a ) % Total T cells (CD3 + ). Arm A: Minima=51, Maxima=99, Median=97, 25th Percentile=95, 75th Percentile=99; Arms B/C: Minima=31, Maxima=100, Median=97, 25th Percentile=94, 75th Percentile=98. b ) % CD4 + T cells (CD3 + CD4+ of CD45 + ). Arm A: Minima=0.50, Maxima=88, Median=16, 25th Percentile=2.6, 75th Percentile=38; Arms B/C: Minima=0.40, Maxima=55, Median=9.9, 25th Percentile=6.1, 75th Percentile=17. c ) %CD8 + T cells (% CD3 + CD8+ of CD45 + ). Arm A: Minima=4.3, Maxima=88, Median=37, 25th Percentile=22, 75th Percentile=47; Arms B/C: Minima=19, Maxima=91, Median=51, 25th Percentile=36, 75th Percentile=71. d ) % αβ T cells (% TCRαβ+ of CD3 + ). Arm A: Minima=8.2, Maxima=94, Median=69, 25th Percentile=28, 75th Percentile=86; Arms B/C: Minima=32, Maxima=98, Median=71, 25th Percentile=48, 75th Percentile=84. e ) % γδ T cells (% TCRγδ+ of CD3 + ). Arm A: Minima=5.1, Maxima=79, Median=28, 25th Percentile=8.4, 75th Percentile=67; Arms B/C: Minima=1.1, Maxima=83, Median=25, 25th Percentile=10, 75th Percentile=53. f ) % CD3 + <t>CD16</t> + CD56+ of CD45 + . Arm A: Minima=2.8, Maxima=25, Median=11, 25th Percentile=7.2, 75th Percentile=17; Arms B/C: Minima=3.4, Maxima=64, Median=16, 25th Percentile=8.1, 75th Percentile=28. g ) % NK cells (CD16/CD56 + CD3- of CD45 + ). Arm A: Minima=0.40, Maxima=48, Median=1.0, 25th Percentile=0.48, 75th Percentile=4.6; Arms B/C: Minima=0.10, Maxima=62, Median=1.6, 25th Percentile=0.60, 75th Percentile=6.1. h - i ) IFNγ ELISpot with background correction for Arm A ( h ) and Arms B/C ( i ). Negative values after background normalization have been normalized to zero for visual representation.
    Cd16 Pe, supplied by Miltenyi Biotec, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/cd16/CD8+Antibody%2C+anti-human%2C+REAfinity/pmc13375545-450-13-15
    Average 95 stars, based on 1 article reviews
    cd16 pe - by Bioz Stars, 2026-09
    95/100 stars
    		  Buy from Supplier
    anti mouse cd16 cd32  (Biocell Technology)
    86
    Biocell Technology anti mouse cd16 cd32
    Flow immunophenotyping release testing data are presented in A-G and IFNγ ELISpot data presented in H-K (Arm A: n = 12; Arms B/C: n = 27). Each data point represents a separate TAA-T cell product infused into patients (biological replicates). Lower whisker is defined as the minima, upper whisker is defined as the maxima, center is defined as median, lower bound of box is defined as Q1 (25th percentile), and upper bound of box is defined as Q3 (75th percentile). a ) % Total T cells (CD3 + ). Arm A: Minima=51, Maxima=99, Median=97, 25th Percentile=95, 75th Percentile=99; Arms B/C: Minima=31, Maxima=100, Median=97, 25th Percentile=94, 75th Percentile=98. b ) % CD4 + T cells (CD3 + CD4+ of CD45 + ). Arm A: Minima=0.50, Maxima=88, Median=16, 25th Percentile=2.6, 75th Percentile=38; Arms B/C: Minima=0.40, Maxima=55, Median=9.9, 25th Percentile=6.1, 75th Percentile=17. c ) %CD8 + T cells (% CD3 + CD8+ of CD45 + ). Arm A: Minima=4.3, Maxima=88, Median=37, 25th Percentile=22, 75th Percentile=47; Arms B/C: Minima=19, Maxima=91, Median=51, 25th Percentile=36, 75th Percentile=71. d ) % αβ T cells (% TCRαβ+ of CD3 + ). Arm A: Minima=8.2, Maxima=94, Median=69, 25th Percentile=28, 75th Percentile=86; Arms B/C: Minima=32, Maxima=98, Median=71, 25th Percentile=48, 75th Percentile=84. e ) % γδ T cells (% TCRγδ+ of CD3 + ). Arm A: Minima=5.1, Maxima=79, Median=28, 25th Percentile=8.4, 75th Percentile=67; Arms B/C: Minima=1.1, Maxima=83, Median=25, 25th Percentile=10, 75th Percentile=53. f ) % CD3 + <t>CD16</t> + CD56+ of CD45 + . Arm A: Minima=2.8, Maxima=25, Median=11, 25th Percentile=7.2, 75th Percentile=17; Arms B/C: Minima=3.4, Maxima=64, Median=16, 25th Percentile=8.1, 75th Percentile=28. g ) % NK cells (CD16/CD56 + CD3- of CD45 + ). Arm A: Minima=0.40, Maxima=48, Median=1.0, 25th Percentile=0.48, 75th Percentile=4.6; Arms B/C: Minima=0.10, Maxima=62, Median=1.6, 25th Percentile=0.60, 75th Percentile=6.1. h - i ) IFNγ ELISpot with background correction for Arm A ( h ) and Arms B/C ( i ). Negative values after background normalization have been normalized to zero for visual representation.
    Anti Mouse Cd16 Cd32, supplied by Biocell Technology, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/cd16/anti+cd16+cd32+invivomab+mouse/pmc08628544-659-7-9
    Average 86 stars, based on 1 article reviews
    anti mouse cd16 cd32 - by Bioz Stars, 2026-09
    86/100 stars
    		  Buy from Supplier
    invivomab anti mouse cd16 cd32  (Biocell Technology)
    86
    Biocell Technology invivomab anti mouse cd16 cd32
    Flow immunophenotyping release testing data are presented in A-G and IFNγ ELISpot data presented in H-K (Arm A: n = 12; Arms B/C: n = 27). Each data point represents a separate TAA-T cell product infused into patients (biological replicates). Lower whisker is defined as the minima, upper whisker is defined as the maxima, center is defined as median, lower bound of box is defined as Q1 (25th percentile), and upper bound of box is defined as Q3 (75th percentile). a ) % Total T cells (CD3 + ). Arm A: Minima=51, Maxima=99, Median=97, 25th Percentile=95, 75th Percentile=99; Arms B/C: Minima=31, Maxima=100, Median=97, 25th Percentile=94, 75th Percentile=98. b ) % CD4 + T cells (CD3 + CD4+ of CD45 + ). Arm A: Minima=0.50, Maxima=88, Median=16, 25th Percentile=2.6, 75th Percentile=38; Arms B/C: Minima=0.40, Maxima=55, Median=9.9, 25th Percentile=6.1, 75th Percentile=17. c ) %CD8 + T cells (% CD3 + CD8+ of CD45 + ). Arm A: Minima=4.3, Maxima=88, Median=37, 25th Percentile=22, 75th Percentile=47; Arms B/C: Minima=19, Maxima=91, Median=51, 25th Percentile=36, 75th Percentile=71. d ) % αβ T cells (% TCRαβ+ of CD3 + ). Arm A: Minima=8.2, Maxima=94, Median=69, 25th Percentile=28, 75th Percentile=86; Arms B/C: Minima=32, Maxima=98, Median=71, 25th Percentile=48, 75th Percentile=84. e ) % γδ T cells (% TCRγδ+ of CD3 + ). Arm A: Minima=5.1, Maxima=79, Median=28, 25th Percentile=8.4, 75th Percentile=67; Arms B/C: Minima=1.1, Maxima=83, Median=25, 25th Percentile=10, 75th Percentile=53. f ) % CD3 + <t>CD16</t> + CD56+ of CD45 + . Arm A: Minima=2.8, Maxima=25, Median=11, 25th Percentile=7.2, 75th Percentile=17; Arms B/C: Minima=3.4, Maxima=64, Median=16, 25th Percentile=8.1, 75th Percentile=28. g ) % NK cells (CD16/CD56 + CD3- of CD45 + ). Arm A: Minima=0.40, Maxima=48, Median=1.0, 25th Percentile=0.48, 75th Percentile=4.6; Arms B/C: Minima=0.10, Maxima=62, Median=1.6, 25th Percentile=0.60, 75th Percentile=6.1. h - i ) IFNγ ELISpot with background correction for Arm A ( h ) and Arms B/C ( i ). Negative values after background normalization have been normalized to zero for visual representation.
    Invivomab Anti Mouse Cd16 Cd32, supplied by Biocell Technology, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/cd16/anti+cd16+cd32+invivomab+mouse/pmc08628544-1153-0-4
    Average 86 stars, based on 1 article reviews
    invivomab anti mouse cd16 cd32 - by Bioz Stars, 2026-09
    86/100 stars
    		  Buy from Supplier
    anti cd16  (Affinity Biosciences)
    86
    Affinity Biosciences anti cd16
    Flow immunophenotyping release testing data are presented in A-G and IFNγ ELISpot data presented in H-K (Arm A: n = 12; Arms B/C: n = 27). Each data point represents a separate TAA-T cell product infused into patients (biological replicates). Lower whisker is defined as the minima, upper whisker is defined as the maxima, center is defined as median, lower bound of box is defined as Q1 (25th percentile), and upper bound of box is defined as Q3 (75th percentile). a ) % Total T cells (CD3 + ). Arm A: Minima=51, Maxima=99, Median=97, 25th Percentile=95, 75th Percentile=99; Arms B/C: Minima=31, Maxima=100, Median=97, 25th Percentile=94, 75th Percentile=98. b ) % CD4 + T cells (CD3 + CD4+ of CD45 + ). Arm A: Minima=0.50, Maxima=88, Median=16, 25th Percentile=2.6, 75th Percentile=38; Arms B/C: Minima=0.40, Maxima=55, Median=9.9, 25th Percentile=6.1, 75th Percentile=17. c ) %CD8 + T cells (% CD3 + CD8+ of CD45 + ). Arm A: Minima=4.3, Maxima=88, Median=37, 25th Percentile=22, 75th Percentile=47; Arms B/C: Minima=19, Maxima=91, Median=51, 25th Percentile=36, 75th Percentile=71. d ) % αβ T cells (% TCRαβ+ of CD3 + ). Arm A: Minima=8.2, Maxima=94, Median=69, 25th Percentile=28, 75th Percentile=86; Arms B/C: Minima=32, Maxima=98, Median=71, 25th Percentile=48, 75th Percentile=84. e ) % γδ T cells (% TCRγδ+ of CD3 + ). Arm A: Minima=5.1, Maxima=79, Median=28, 25th Percentile=8.4, 75th Percentile=67; Arms B/C: Minima=1.1, Maxima=83, Median=25, 25th Percentile=10, 75th Percentile=53. f ) % CD3 + <t>CD16</t> + CD56+ of CD45 + . Arm A: Minima=2.8, Maxima=25, Median=11, 25th Percentile=7.2, 75th Percentile=17; Arms B/C: Minima=3.4, Maxima=64, Median=16, 25th Percentile=8.1, 75th Percentile=28. g ) % NK cells (CD16/CD56 + CD3- of CD45 + ). Arm A: Minima=0.40, Maxima=48, Median=1.0, 25th Percentile=0.48, 75th Percentile=4.6; Arms B/C: Minima=0.10, Maxima=62, Median=1.6, 25th Percentile=0.60, 75th Percentile=6.1. h - i ) IFNγ ELISpot with background correction for Arm A ( h ) and Arms B/C ( i ). Negative values after background normalization have been normalized to zero for visual representation.
    Anti Cd16, supplied by Affinity Biosciences, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/cd16/anti+cd16/pm42298950-94-45-47
    Average 86 stars, based on 1 article reviews
    anti cd16 - by Bioz Stars, 2026-09
    86/100 stars
    		  Buy from Supplier

    Image Search Results


    Flow immunophenotyping release testing data are presented in A-G and IFNγ ELISpot data presented in H-K (Arm A: n = 12; Arms B/C: n = 27). Each data point represents a separate TAA-T cell product infused into patients (biological replicates). Lower whisker is defined as the minima, upper whisker is defined as the maxima, center is defined as median, lower bound of box is defined as Q1 (25th percentile), and upper bound of box is defined as Q3 (75th percentile). a ) % Total T cells (CD3 + ). Arm A: Minima=51, Maxima=99, Median=97, 25th Percentile=95, 75th Percentile=99; Arms B/C: Minima=31, Maxima=100, Median=97, 25th Percentile=94, 75th Percentile=98. b ) % CD4 + T cells (CD3 + CD4+ of CD45 + ). Arm A: Minima=0.50, Maxima=88, Median=16, 25th Percentile=2.6, 75th Percentile=38; Arms B/C: Minima=0.40, Maxima=55, Median=9.9, 25th Percentile=6.1, 75th Percentile=17. c ) %CD8 + T cells (% CD3 + CD8+ of CD45 + ). Arm A: Minima=4.3, Maxima=88, Median=37, 25th Percentile=22, 75th Percentile=47; Arms B/C: Minima=19, Maxima=91, Median=51, 25th Percentile=36, 75th Percentile=71. d ) % αβ T cells (% TCRαβ+ of CD3 + ). Arm A: Minima=8.2, Maxima=94, Median=69, 25th Percentile=28, 75th Percentile=86; Arms B/C: Minima=32, Maxima=98, Median=71, 25th Percentile=48, 75th Percentile=84. e ) % γδ T cells (% TCRγδ+ of CD3 + ). Arm A: Minima=5.1, Maxima=79, Median=28, 25th Percentile=8.4, 75th Percentile=67; Arms B/C: Minima=1.1, Maxima=83, Median=25, 25th Percentile=10, 75th Percentile=53. f ) % CD3 + CD16 + CD56+ of CD45 + . Arm A: Minima=2.8, Maxima=25, Median=11, 25th Percentile=7.2, 75th Percentile=17; Arms B/C: Minima=3.4, Maxima=64, Median=16, 25th Percentile=8.1, 75th Percentile=28. g ) % NK cells (CD16/CD56 + CD3- of CD45 + ). Arm A: Minima=0.40, Maxima=48, Median=1.0, 25th Percentile=0.48, 75th Percentile=4.6; Arms B/C: Minima=0.10, Maxima=62, Median=1.6, 25th Percentile=0.60, 75th Percentile=6.1. h - i ) IFNγ ELISpot with background correction for Arm A ( h ) and Arms B/C ( i ). Negative values after background normalization have been normalized to zero for visual representation.

    Journal: Nature Medicine

    Article Title: Multi-antigen-targeting T cells in pediatric central nervous system tumors: a phase 1 trial

    doi: 10.1038/s41591-026-04449-9

    Figure Lengend Snippet: Flow immunophenotyping release testing data are presented in A-G and IFNγ ELISpot data presented in H-K (Arm A: n = 12; Arms B/C: n = 27). Each data point represents a separate TAA-T cell product infused into patients (biological replicates). Lower whisker is defined as the minima, upper whisker is defined as the maxima, center is defined as median, lower bound of box is defined as Q1 (25th percentile), and upper bound of box is defined as Q3 (75th percentile). a ) % Total T cells (CD3 + ). Arm A: Minima=51, Maxima=99, Median=97, 25th Percentile=95, 75th Percentile=99; Arms B/C: Minima=31, Maxima=100, Median=97, 25th Percentile=94, 75th Percentile=98. b ) % CD4 + T cells (CD3 + CD4+ of CD45 + ). Arm A: Minima=0.50, Maxima=88, Median=16, 25th Percentile=2.6, 75th Percentile=38; Arms B/C: Minima=0.40, Maxima=55, Median=9.9, 25th Percentile=6.1, 75th Percentile=17. c ) %CD8 + T cells (% CD3 + CD8+ of CD45 + ). Arm A: Minima=4.3, Maxima=88, Median=37, 25th Percentile=22, 75th Percentile=47; Arms B/C: Minima=19, Maxima=91, Median=51, 25th Percentile=36, 75th Percentile=71. d ) % αβ T cells (% TCRαβ+ of CD3 + ). Arm A: Minima=8.2, Maxima=94, Median=69, 25th Percentile=28, 75th Percentile=86; Arms B/C: Minima=32, Maxima=98, Median=71, 25th Percentile=48, 75th Percentile=84. e ) % γδ T cells (% TCRγδ+ of CD3 + ). Arm A: Minima=5.1, Maxima=79, Median=28, 25th Percentile=8.4, 75th Percentile=67; Arms B/C: Minima=1.1, Maxima=83, Median=25, 25th Percentile=10, 75th Percentile=53. f ) % CD3 + CD16 + CD56+ of CD45 + . Arm A: Minima=2.8, Maxima=25, Median=11, 25th Percentile=7.2, 75th Percentile=17; Arms B/C: Minima=3.4, Maxima=64, Median=16, 25th Percentile=8.1, 75th Percentile=28. g ) % NK cells (CD16/CD56 + CD3- of CD45 + ). Arm A: Minima=0.40, Maxima=48, Median=1.0, 25th Percentile=0.48, 75th Percentile=4.6; Arms B/C: Minima=0.10, Maxima=62, Median=1.6, 25th Percentile=0.60, 75th Percentile=6.1. h - i ) IFNγ ELISpot with background correction for Arm A ( h ) and Arms B/C ( i ). Negative values after background normalization have been normalized to zero for visual representation.

    Article Snippet: Antibodies for the T/NK panel included CD8 FITC (Miltenyi Biotec, cat. no. 130-110-677), CD16 PE (Miltenyi Biotec, cat. no. 130-113-393), CD56 PE (Miltenyi Biotec, cat. no. 130-113-312), CD3 Per CP Vio-770 (Miltenyi Biotec, cat. no. 130-113-141), CD4 PE-Vio-770 (Miltenyi Biotec, cat. no. 130-113-227) and CD45 APC (Miltenyi Biotec, cat. no. 130-110-633).

    Techniques: Enzyme-linked Immunospot, Whisker Assay